Article

Tips for integrating APPs into your practice

Author(s):

Anne E. Calvaresi, DNP, CRNP, RNFA
Conference|AUA

Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.

The aging urologist population has heightened the importance of advanced-practice providers (APPs) in urology practices, says Anne E. Calvaresi, DNP, CRNP, RNFA, a nurse practitioner at Thomas Jefferson University Hospital in Philadelphia.

Dr. Calvaresi, in this Urology Times video, offers some practical tips for integrating nurse practitioners and physician assistants into your urology practice. She also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.

 

 

Related Videos
5 key trial insights from AUA 2025
5 key trial insights from AUA 2025
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
May 5th 2025

AUA 2025 recap: Urologic oncology trials in progress

Hannah Clarke
Take a look through some of the notable studies that were spotlighted during this year’s meeting.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
May 2nd 2025

TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

Hannah Clarke
Data showed an overall CR rate of 82.4%.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
© 2025 MJH Life Sciences

All rights reserved.